1. A class action lawsuit against BioAge Labs has been initiated for misleading information. 2. The lawsuit follows a significant stock price drop after Phase 2 trial discontinuation. 3. BioAge's initial public offering touted azelaprag as a promising therapy candidate. 4. Safety concerns over liver transaminase levels led to the trial's termination.
The lawsuit highlights severe issues with misrepresentation impacting investor trust. Similar past occurrences in biotech firms have led to long-term price declines.
The class action lawsuit is critical and indicates serious governance issues at BioAge.
Pending outcomes of the class action could affect investor sentiment and stock stability long-term.
The Gross Law Firm issues the following notice to shareholders of BioAge Labs, Inc. (NASDAQ: BIOA).
Shareholders who purchased shares of BIOA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
https://securitiesclasslaw.com/securities/bioage-labs-inc-loss-submission-form/?id=126276&from=4
This lawsuit is on behalf of all shareholders that purchased stock pursuant and/or traceable to BioAge's registration statement for the initial public offering held on or about September 26, 2024.
According to the complaint, on December 6, 2024, BioAge announced that it would discontinue the ongoing STRIDES Phase 2 trial for azelaprag, its lead product candidate, citing safety concerns over elevated liver transaminase levels in participants. This came as a surprise because, at the time of its IPO less than three months earlier, BioAge highlighted azelaprag's potential in patients undergoing obesity therapy with incretin drugs. Following this news, BioAge's stock price declined from $20.09 per share on December 6, 2024 to $4.65 per share on December 7, 2024.
March 10, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/bioage-labs-inc-loss-submission-form/?id=126276&from=4
Once you register as a shareholder who purchased shares of BIOA during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is March 10, 2025. There is no cost or obligation to you to participate in this case.
The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: info@grosslawfirm.com
Phone: (646) 453-8903
The Gross Law Firm